Tilray posts $434 million net loss for 2022
Tilray just posted $434 million net loss for its 2022 fiscal year.
The net loss includes a $395 million noncash impairment charge “primarily impacting inventory, goodwill and other intangible assets.”
On a Thursday conference call with analysts and investors, Tilray CEO Irwin Simon attributed the impairment charge to “both market conditions and the work that we have done to optimize our operations.”
Simon said the company now aims to generate up to $4 billion in revenue by the end of its 2024 fiscal year, “depending upon federal (cannabis) legalization in the U.S. and Germany.”
Tilray’s net revenue for the 2022 fiscal year was $628.4 million, representing growth of 22.5% over the previous fiscal year.
By the end of Tilray’s 2023 fiscal year, Simon said the company expects to be free cash-flow positive and achieve $100 million in cost savings following its megamerger with Aphria.
The company said it has already realized $85 million in cost synergies related to that merger.
In Europe, Tilray’s chief strategy officer and head of international, Denise Faltischek, said the company expects “to establish ourselves as a market leader to broadly legalize (the) adult-use cannabis market in Germany, and seize a sizable portion of that market.”
Faltischek said Tilray believes “all of Europe could legalize medical-use cannabis within the next two years or sooner, with certain countries legalizing adult-use shortly thereafter.”
Blair MacNeil, president of Tilray’s Canadian business, said the domestic cannabis market is challenging, “characterized by an oversupply of cannabis, unreasonable regulatory barriers, and punitive excise taxation exacerbated by price compression.”
MacNeil said Tilray’s Canadian adult-use market share declined from 10.2% to 8.3% in the previous quarter, citing “challenging industry conditions, (stock-keeping unit) rationalizations and discontinuation of partner brands.”
However, MacNeil said Tilray believes that trend will reverse as the result of improvements to its cannabis flower portfolio.
Tilray’s adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) for the fourth quarter were $11.5 million, a 13.9% increase over the previous quarter’s adjusted EBITDA.
Net revenue for the fourth quarter grew to $153.3 million, an increase of 0.9% over Tilray’s previous quarter.
The company’s annual net revenue of $628.4 million consisted of 38% cannabis revenue, 42% distribution revenue, 11% beverage alcohol revenue and 9% wellness revenue.
Tilray posts $434 million net loss for 2022
About Cannin: Your Cannabis Stocks Resource
78% of Cannin’s fundamentals prove true within 30 days or less on 100+ recommendations over the past 2 years.
Cannin is your #1 trusted resource for cannabis stocks. Our global team of experts evaluates all emerging cannabis stock investing opportunities. In fact, we aggregate hundreds of hours of financial research and provide tips on the best cannabis stocks for 2021.
Use Cannin as your resource for:
Market analysts expect the marijuana and hemp industry will have an annual value exceeding $75 Billion in the next decade. Is it too late to invest in marijuana stocks? No! This is the perfect time to invest.
Are you looking to buy stock in hemp companies or marijuana companies for 2021? If so, are you interested in new penny hemp stock companies? Or, looking for the best Canadian cannabis stocks to invest in? Maybe, you’re looking to leverage the power of algorithmic stock trading to beat the cannabis market? We can help.
Are you interested in cannabis stocks like Curaleaf, Trulieve, Aurora Cannabis, Charlotte’s Web, Canopy Growth, or Hemp Inc.?
Predict price movements of cannabis stocks several hours in advance with our proprietary algorithmic stock trading software.
- +34% Gains in 2022
- +56% Gains in 2021
- +30% Gains in 2020
- +49.8% Gains in 2019
- Backtested since 2012
In fact, we’re so confident you’ll love our algotrading cannabis stock signals, we’re willing to give you a one week risk-free trial to see it for yourself.
Profit from the best cannabis stocks – we’ll show you how at cannin.com.
